Reappointed Jeil Pharm CEO Sung Seok-je and Han Sang-cheol as inside directors
Cheil Pharma Holdings and Jeil Pharm each decided to pay a cash dividend of 50 earned per share
[바이오타임즈] Jeil Pharm (CEO Sung Seok-je) announced on the 24th that it is holding the 6th regular shareholder meeting at its headquarters in Seocho-gu, Seoul.
At the general shareholders meeting on this day, Jeil Pharm reported a major business performance, including sales of KRW 725.2 billion last year.
In addition, seven items were approved, including the reappointment of CEO Seok-je Seong and President Sang-cheol Han as internal directors, the appointment of new external directors and auditors, and the approval of the limit on directors’ remuneration.
Seong Seok-je, CEO of Jeil Pharm, said in his greeting, “Despite a series of changes and crises, we have achieved sustainable growth by wisely overcoming the rapidly changing business environment.” Although it presents many management difficulties, we will use this environment as a starting point for a leap forward to innovate a bigger future.”
On the same day, Jeil Pharma Holdings also held the 63rd regular general meeting of shareholders, and six agenda items were approved, including financial statements and consolidated financial statements, reappointment and new appointment of internal and external directors, as originally proposed.
Meanwhile, Jeil Pharma Holdings and Jeil Pharm decided to pay a cash dividend of 50 earned per share.
[바이오타임즈=김수진 기자] sjkimcap@biotimes.co.kr
Copyright © Biotimes Unauthorized reproduction and redistribution prohibited
